Glucophage

How to order Glucophage

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Glucophage on Prescriptsy

Glucophage is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Glucophage is the branded form of metformin hydrochloride, a biguanide medicine prescribed as first-line pharmacological treatment for type 2 diabetes mellitus.

It is manufactured by Merck and available as immediate-release tablets (500 mg, 850 mg, and 1000 mg) and as the modified-release formulation Glucophage SR.

Metformin is the most widely prescribed antidiabetic medicine worldwide and the cornerstone of type 2 diabetes management.

This page provides a comprehensive clinical overview of Glucophage, including how it works, dosing guidance, side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Type 2 diabetes affects approximately 4.3 million people in the UK, with a further 2.4 million estimated to be at high risk of developing the condition.

It is a chronic metabolic disorder characterised by insulin resistance and progressive beta-cell dysfunction, leading to elevated blood glucose levels.

Sustained high blood sugar damages blood vessels and nerves throughout the body, increasing the risk of cardiovascular disease, stroke, kidney failure, blindness, and lower-limb amputation.

Early diagnosis and effective treatment are essential to reduce these risks and improve quality of life.

Important safety information about Glucophage

Before reading further, note the following essential safety points about Glucophage.

• Glucophage is a prescription-only medicine (POM) and must be used under medical supervision.
• Take tablets with or immediately after food to reduce gastrointestinal side effects.
• Stop taking Glucophage and seek emergency medical attention if you develop symptoms of lactic acidosis: unusual muscle pain, difficulty breathing, stomach pain, or feeling generally very unwell.
• Your kidney function must be checked before starting and at least annually during treatment.
• Tell your doctor if you are having surgery, an imaging scan with contrast dye, or if you become seriously unwell, as Glucophage may need to be temporarily stopped.

Understanding type 2 diabetes

In a healthy individual, the pancreas produces insulin in response to rising blood glucose levels after eating.

Insulin enables cells in muscles, fat tissue, and the liver to take up glucose from the bloodstream and use it for energy or store it for later use.

In type 2 diabetes, cells become resistant to the action of insulin, meaning the pancreas must produce progressively more insulin to maintain normal blood glucose levels.

Over time, the beta cells in the pancreas cannot keep up with demand, and blood glucose rises above normal.

Risk factors for type 2 diabetes include being overweight or obese (particularly carrying excess weight around the waist), physical inactivity, a family history of diabetes, age over 40 (or over 25 in South Asian, Black African, and African-Caribbean populations), a history of gestational diabetes, and polycystic ovary syndrome.

Type 2 diabetes often develops gradually and may be present for years before diagnosis, as early symptoms are subtle.

Common symptoms include excessive thirst, frequent urination, fatigue, blurred vision, slow wound healing, and recurrent infections.

Diagnosis is confirmed by blood tests. An HbA1c of 48 mmol/mol (6.5%) or above on two separate occasions is diagnostic of type 2 diabetes.

A fasting plasma glucose of 7.0 mmol/L or higher, or a random plasma glucose of 11.1 mmol/L or higher with symptoms, also confirms the diagnosis.

NICE guideline NG28 provides the framework for diagnosis and management of type 2 diabetes in adults in the UK.

How Glucophage works: mechanism of action

Metformin, the active ingredient in Glucophage, works through several complementary mechanisms that do not depend on functioning pancreatic beta cells.

Its primary action is to reduce hepatic glucose production by inhibiting gluconeogenesis (the process by which the liver manufactures new glucose from non-carbohydrate sources).

This addresses one of the key drivers of fasting hyperglycaemia in type 2 diabetes.

Metformin also enhances insulin sensitivity in peripheral tissues, particularly skeletal muscle, enabling cells to take up glucose more effectively from the bloodstream.

It activates AMP-activated protein kinase (AMPK), an enzyme that plays a central role in cellular energy regulation.

Activation of AMPK improves glucose transport, fatty acid oxidation, and mitochondrial function.

A third mechanism involves delayed absorption of glucose from the gastrointestinal tract. This contributes to a smoother post-meal glucose profile.

Unlike sulphonylureas or meglitinides, metformin does not stimulate insulin secretion. This means it does not cause hypoglycaemia when used as monotherapy and does not promote weight gain.

In clinical trials and real-world practice, metformin is associated with weight stability or modest weight loss, making it particularly appropriate for the majority of patients with type 2 diabetes who are overweight.

Clinical evidence and UK prescribing guidance

The landmark UK Prospective Diabetes Study (UKPDS), published in 1998, demonstrated that metformin significantly reduced the risk of diabetes-related death, all-cause mortality, and myocardial infarction in overweight patients with newly diagnosed type 2 diabetes, compared with conventional treatment.

Metformin was the only glucose-lowering agent in UKPDS to show a mortality benefit, and this advantage persisted for at least 10 years after the trial ended (UKPDS post-trial monitoring study).

These findings established metformin as the preferred first-line therapy for type 2 diabetes worldwide.

NICE guideline NG28 recommends metformin as the initial drug treatment for adults with type 2 diabetes.

Standard-release metformin should be offered first, with a switch to modified-release if gastrointestinal side effects are intolerable.

If HbA1c rises above the individual's target (usually 48 mmol/mol for monotherapy, increasing to 53 or 58 mmol/mol at subsequent intensification steps), additional agents are added to metformin.

Options for second-line therapy alongside metformin include sulphonylureas, DPP-4 inhibitors, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists.

The choice depends on the patient's cardiovascular risk profile, body weight, risk of hypoglycaemia, and renal function.

Metformin is also used off-label for polycystic ovary syndrome (PCOS) to improve insulin resistance and may be used during pregnancy for gestational diabetes under specialist supervision, though insulin remains the standard treatment in pregnancy.

Glucophage versus generic metformin

Glucophage is the original branded formulation of metformin, first approved in the UK in the 1950s.

Generic metformin tablets contain the same active ingredient at the same strength and are therapeutically equivalent.

The vast majority of metformin prescribed in UK general practice is dispensed as generic metformin, which is one of the least expensive medicines in the NHS formulary.

Glucophage SR (sustained-release) may be preferred for patients who experience gastrointestinal intolerance with standard-release tablets, as the modified-release formulation produces lower peak plasma concentrations and delivers the drug more gradually.

Dosage and administration

For adults taking Glucophage immediate-release, the recommended starting dose is 500 mg once or twice daily with meals.

The dose is increased gradually every 1 to 2 weeks until the target HbA1c is achieved or the maximum tolerated dose is reached.

The usual effective maintenance dose is 1500 to 2000 mg daily in divided doses.

The maximum daily dose is 3000 mg, though most patients do not need more than 2000 mg.

For Glucophage SR, the starting dose is 500 mg once daily with the evening meal, increased by 500 mg every 1 to 2 weeks to a maximum of 2000 mg once daily.

If 2000 mg once daily does not achieve adequate control, 1000 mg twice daily may be tried.

Take immediate-release tablets with or immediately after meals. This reduces gastrointestinal side effects and improves absorption. Modified-release tablets should be swallowed whole and not crushed or chewed.

Dose adjustments are required for patients with impaired kidney function. In patients with an eGFR of 45 to 59, the maximum dose is 1000 mg daily.

In those with an eGFR of 30 to 44, the starting dose is 500 mg once daily and the maximum is 1000 mg daily.

Metformin must not be started if eGFR is below 30 and must be stopped if eGFR falls below 30 during treatment.

Side effects of Glucophage

Very common and common side effects

Gastrointestinal symptoms are the most frequently reported side effects and include nausea, vomiting, diarrhoea, abdominal pain, bloating, and loss of appetite.

These effects occur in up to 25% of patients starting treatment and are the most common reason for discontinuation.

They are dose-related and usually transient, resolving within 2 to 4 weeks.

Slow dose titration (increasing by no more than 500 mg per week) and taking tablets with food are the most effective strategies for reducing gastrointestinal intolerance.

If symptoms persist despite slow titration, switching to Glucophage SR often resolves the problem.

A metallic or altered taste in the mouth affects some patients and typically resolves without intervention.

Uncommon and rare side effects

Long-term metformin use is associated with decreased vitamin B12 absorption in approximately 5 to 10% of patients.

This can lead to vitamin B12 deficiency, which may present as megaloblastic anaemia, peripheral neuropathy, or cognitive impairment.

The BNF recommends periodic monitoring of vitamin B12 levels, particularly in patients on long-term therapy or those with symptoms suggestive of deficiency.

Supplementation with oral or intramuscular vitamin B12 may be required.

Skin reactions including erythema, pruritus, and urticaria are rare. Hepatitis and abnormal liver function tests have been reported very rarely and usually resolve on discontinuation.

Lactic acidosis

Lactic acidosis is extremely rare (estimated at 3 to 10 cases per 100,000 patient-years) but carries a mortality rate of approximately 50%.

It occurs when metformin accumulates to toxic levels, most commonly in the context of acute kidney injury, severe dehydration, sepsis, or conditions causing tissue hypoxia.

Symptoms include nausea, vomiting, abdominal pain, hyperventilation (deep, rapid breathing), muscle cramps, hypothermia, and progressive drowsiness.

If you develop any combination of these symptoms, stop taking Glucophage immediately and call 999. Treatment is supportive and may include haemodialysis to remove metformin from the blood.

When to seek urgent medical advice

Contact your GP or call NHS 111 if you experience persistent or severe gastrointestinal symptoms, unusual fatigue, tingling or numbness in your hands or feet, or any new symptom that concerns you.

Call 999 or attend A&E if you develop symptoms of lactic acidosis (described above), signs of severe hypoglycaemia (if taking metformin with sulphonylureas or insulin), or any life-threatening symptoms.

Report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Glucophage must not be used in patients with diabetic ketoacidosis, diabetic pre-coma, severe renal impairment (eGFR below 30), acute conditions with the potential to alter renal function (dehydration, severe infection, shock), acute or chronic disease that may cause tissue hypoxia (cardiac failure, respiratory failure, recent myocardial infarction), hepatic insufficiency, acute alcohol intoxication, or alcoholism.

It is also contraindicated in patients with known hypersensitivity to metformin or any excipient.

Renal function monitoring

The kidneys are the sole route of metformin elimination. Any decline in renal function can lead to accumulation and increase the risk of lactic acidosis.

Renal function (eGFR) must be assessed before starting Glucophage and at least annually during treatment.

In patients with additional risk factors for renal impairment (such as elderly patients, those taking ACE inhibitors or ARBs, or those with heart failure), monitoring should be more frequent (every 3 to 6 months).

Dose reductions are required for mild to moderate renal impairment, and metformin must be stopped if eGFR falls below 30.

Surgical procedures and contrast media

Metformin should be stopped 48 hours before elective surgery under general anaesthesia and not restarted until at least 48 hours after the procedure, once renal function has been confirmed as stable.

Before imaging procedures using iodinated contrast agents (such as CT scans with contrast), metformin should be stopped at the time of or before the procedure and not restarted for at least 48 hours, after renal function has been rechecked.

Iodinated contrast can cause acute kidney injury, which would impair metformin excretion.

Alcohol

Excessive alcohol intake increases the risk of lactic acidosis by impairing hepatic lactate metabolism. Patients should limit alcohol consumption while taking metformin. Binge drinking should be avoided entirely.

Pregnancy and breastfeeding

Metformin crosses the placenta. It may be used during pregnancy for gestational diabetes or pre-existing type 2 diabetes under specialist supervision, though insulin is generally preferred.

Metformin is excreted in breast milk at low levels and is considered compatible with breastfeeding, though individual advice should be sought from your prescriber.

How to get Glucophage in the UK

Glucophage is a prescription-only medicine available on the NHS.

Your GP will prescribe it following a diagnosis of type 2 diabetes, based on blood tests (HbA1c and fasting glucose) and a comprehensive clinical assessment.

Regular monitoring appointments will be arranged to track your blood sugar, kidney function, and overall diabetes management.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also prescribe metformin after an appropriate clinical consultation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Most patients with diabetes in England can apply for a medical exemption certificate, which entitles them to free prescriptions for all conditions.

Living with type 2 diabetes: lifestyle alongside Glucophage

Medication is one component of managing type 2 diabetes.

NICE recommends a holistic approach incorporating dietary changes (a balanced diet rich in vegetables, wholegrains, and lean protein, with reduced intake of refined carbohydrates and sugary foods), regular physical activity (at least 150 minutes of moderate-intensity exercise per week), weight management (even modest weight loss of 5 to 10% can significantly improve blood sugar control), smoking cessation, and managing blood pressure and cholesterol.

Structured education programmes such as DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) or X-PERT are available through the NHS and can help you understand and manage your condition effectively.

Monitor your blood sugar as advised by your diabetes team. Attend all review appointments, including annual checks for eyes (diabetic retinopathy screening), feet, kidneys, blood pressure, and cholesterol. Early detection and treatment of complications can prevent serious harm.

Sources

• Glucophage 500 mg, 850 mg, 1000 mg Film-Coated Tablets, Summary of Product Characteristics (EMC)
• Metformin hydrochloride, British National Formulary (BNF)
• NICE NG28: Type 2 diabetes in adults: management
• Type 2 diabetes, NHS
• Metformin, NHS medicines guide
• MHRA Yellow Card Scheme